Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
McKinsey
Fuji
Cantor Fitzgerald
AstraZeneca
Accenture
Citi
Baxter
Chinese Patent Office

Generated: May 21, 2018

DrugPatentWatch Database Preview

ACEON Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Aceon, and what generic alternatives are available?

Aceon is a drug marketed by Symplmed Pharms Llc and is included in one NDA.

The generic ingredient in ACEON is perindopril erbumine. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the perindopril erbumine profile page.
Drug patent expirations by year for ACEON
Medical Subject Heading (MeSH) Categories for ACEON
Synonyms for ACEON
(2S,3(infinity)S,7(infinity)S)-1-[(S)-N-[(S)-1-Carboxybutyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1)
(2S,3aS,7aS)-1-((S)-N-((S)-1-Carboxybutyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1)
(2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid tert-butylamine salt
(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; 2-methylpropan-2-amine
(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid;2-methylpropan-2-amine
(2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propanoyl}octahydro-1H-indole-2-carboxylic acid--2-methylpropan-2-amine (1/1)
(2S,3aS,7aS)-1-{(S)-2-[(S)-1-(ethoxycarbonyl)butylamino]propanoyl}octahydroindole-2-carboxylic acid--1,1-dimethylethanamine (1/1)
107133-36-8
133P368
1964X464OJ
1H-indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydo-, (2S-(1R(R*(R*)),2alpha,3abeta,7abeta))_,compd. With 2-methyl-2-propanamine (1:1)
1H-Indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,7abeta))-, compd. with 2-methyl-2-propanamine (1:1)
2-methylpropan-2-amine (2S,3aS,7aS)-1-(((S)-1-ethoxy-1-oxopentan-2-yl)-L-alanyl)octahydro-1H-indole-2-carboxylate
AB0105687
AB2000130
AC-19078
AC1L9AYA
Aceon (TN)
AK161702
AKOS015841351
AKOS015961912
AX8041142
C07707
C19H32N2O5.C4H11N
CAS-107133-36-8
CCG-39035
CHEBI:8025
CHEMBL1200343
Covapril
CP0070
CS-1904
D00624
DSSTox_CID_24198
DSSTox_GSID_44198
DTXSID1044198
HMS1922N07
HMS2093M06
HY-B0130A
IYNMDWMQHSMDDE-MHXJNQAMSA-N
KS-1243
LS-82690
McN-A-2833-109
MFCD02313824
MolPort-003-666-611
NCGC00178276-01
NCGC00357164-01
NSC-758929
NSC758929
Perindopril (erbumine)
PERINDOPRIL ERBUMINE
Perindopril erbumine (JAN/USP)
Perindopril erbumine [USAN]
Perindopril erbumine, United States Pharmacopeia (USP) Reference Standard
Perindopril for peak identification, European Pharmacopoeia (EP) Reference Standard
Perindopril for stereochemical purity, European Pharmacopoeia (EP) Reference Standard
Perindopril tert-butylamine
Perindopril tert-butylamine, European Pharmacopoeia (EP) Reference Standard
Perindopril;Coversyl;Aceon
Pharmakon1600-01505212
S-9490-3
SCHEMBL41679
SPECTRUM1505212
ST24048892
TL8000252
Tox21_303915
UNII-1964X464OJ

US Patents and Regulatory Information for ACEON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-001 Dec 30, 1993 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-002 Dec 30, 1993 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-003 Dec 30, 1993 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for ACEON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-002 Dec 30, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-001 Dec 30, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-003 Dec 30, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-003 Dec 30, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ACEON
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 2 mg, 4 mg and 8 mg ➤ Subscribe 2006-06-06

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Chinese Patent Office
McKesson
Cantor Fitzgerald
Medtronic
Fish and Richardson
Teva
Moodys
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.